InsiderTrades

Form 4 for BCAX Bicara Therapeutics Inc.

Accepted 2026-03-02 00:00:00 ET · period of report 2026-02-26 · accession 0001231919-26-000231 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2026-03-02 2026-02-26 BCAX RA CAPITAL MANAGEMENT, L.P. Dir, 10% P - Purchase $16.00 +300.0K 4.60M +7% +$4.80M
DI 2026-03-02 2026-02-26 BCAX RA CAPITAL MANAGEMENT, L.P. Dir, 10% P - Purchase $16.00 +2.20M 2.20M New +$35.20M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-02-26 P A 300,000 $16.00 4,603,418 I See footnotes — — (F1) RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. (F2) Held directly by the Fund.
2 Derivative Pre-Funded Warrant (Right to Buy) 2026-02-26 P A 2,200,000 $16.00 2,200,000 I See Footnotes $0.00 · — to — 2,200,000 Common Stock (F1) RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. (F2) Held directly by the Fund. (F4) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.